Wall Street Zen Upgrades Immunovant (NASDAQ:IMVT) to Hold

Immunovant logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Immunovant from “sell” to “hold.” Across analysts, the stock has a “Moderate Buy” consensus from nine Buy, three Hold, and one Sell ratings, with an average price target of $44.60.
  • Immunovant reported a quarterly loss of $0.47 per share, beating analysts’ estimate of a $0.74 loss; analysts forecast a loss of $2.78 per share for the current fiscal year.
  • Shares opened at $34.18 and were reported down 2.5%, within a 12-month range of $21.86 to $45.42.
  • MarketBeat previews the top five stocks to own by December 1st.

Immunovant (NASDAQ:IMVT - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other analysts have also issued research reports about the company. HC Wainwright reissued a "buy" rating on shares of Immunovant in a research note on Thursday, September 24th. JPMorgan Chase & Co. boosted their price objective on shares of Immunovant from $47.00 to $50.00 and gave the company an "overweight" rating in a research report on Tuesday, August 4th. Citigroup reissued a "positive" rating on shares of Immunovant in a research report on Thursday, September 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunovant in a research note on Friday, October 2nd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunovant in a research note on Tuesday, August 25th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Immunovant presently has an average rating of "Moderate Buy" and a consensus price target of $44.60.

Read Our Latest Stock Analysis on IMVT

Immunovant Trading Down 2.5%

IMVT opened at $34.18 on Friday. Immunovant has a 12 month low of $21.86 and a 12 month high of $45.42. The business's 50-day moving average price is $32.64 and its 200-day moving average price is $32.33.

Immunovant (NASDAQ:IMVT - Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.27. During the same period in the previous year, the firm earned ($0.73) EPS. On average, equities analysts forecast that Immunovant will post -2.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Immunovant news, COO Melanie Gloria sold 2,241 shares of Immunovant stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $32.06, for a total transaction of $71,846.46. Following the completion of the transaction, the chief operating officer owned 217,060 shares in the company, valued at approximately $6,958,943.60. The trade was a 1.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Tiago Girão sold 6,606 shares of the business's stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $28.50, for a total value of $188,271.00. Following the completion of the sale, the chief financial officer directly owned 234,192 shares in the company, valued at $6,674,472. This trade represents a 2.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 27,430 shares of company stock worth $895,852 over the last three months. Corporate insiders own 1.90% of the company's stock.

Hedge Funds Weigh In On Immunovant

Institutional investors and hedge funds have recently modified their holdings of the stock. Empowered Funds LLC raised its position in shares of Immunovant by 2.7% during the 1st quarter. Empowered Funds LLC now owns 14,556 shares of the company's stock valued at $362,000 after purchasing an additional 381 shares during the period. HighTower Advisors LLC raised its holdings in Immunovant by 0.8% during the third quarter. HighTower Advisors LLC now owns 56,541 shares of the company's stock valued at $1,910,000 after acquiring an additional 437 shares during the period. Corient Private Wealth LP raised its holdings in Immunovant by 1.8% during the second quarter. Corient Private Wealth LP now owns 24,522 shares of the company's stock valued at $945,000 after acquiring an additional 442 shares during the period. GAMMA Investing LLC raised its holdings in Immunovant by 63.6% during the third quarter. GAMMA Investing LLC now owns 1,224 shares of the company's stock valued at $41,000 after acquiring an additional 476 shares during the period. Finally, Kestra Advisory Services LLC lifted its position in shares of Immunovant by 4.5% in the third quarter. Kestra Advisory Services LLC now owns 17,273 shares of the company's stock valued at $583,000 after acquiring an additional 751 shares in the last quarter. 47.08% of the stock is currently owned by institutional investors.

Immunovant Company Profile

(Get Free Report)

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company's investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves' disease and other autoimmune disorders.

Further Reading

Analyst Recommendations for Immunovant (NASDAQ:IMVT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunovant Right Now?

Before you consider Immunovant, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.

While Immunovant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines